Oncology

#Institute of Cancer Research #Oncology #Precision medicine

Combining precision medicines can treat drug-resistant cancers

Launching a dual-pronged attack on tumours using a combination of two innovative precision medicines could treat patients with multiple common cancers, a new clinical trial shows. It is the first trial to use the pioneering genetically targeted drug olaparib – already licensed for ovarian, breast and prostate cancer – together… Read More

#Trending News

#Biologics / Biotechnology #Concarlo Holdings #Oncology

US biotech start-up set to have huge impact on breast cancer treatment landscape

Backed by more than 20 years of research and development expertise, Concarlo Holdings is developing diagnostics and therapeutics that could have huge impact for metastatic breast cancer patients. Lu Rahman finds out more. Stacy Blain, Co-Founder, Concarlo Holdings, wants to change the conversation around breast cancer. This biotechnology start-up whose… Read More

#Cancer Research #Exclusive Content

#AI / data analytics / healthtech / informatics #Analysis #Biomarkers #Cell therapy #Clinical trials #Drug development #Drug targets #Gene therapy #Immunology #Immunology / Virology & Vaccines #Molecular medicine #Oncology #Precision medicine #Preclinical #Protein chemistry / Proteomics #RNA #Screening #Sequencing #Stem cells #Therapeutics #Toxicology #Translational #Translational chemistry

Honing in on perfect targeting

Honing in on perfect targeting By Dr Samantha Zaroff Volume 21 Issue 3 – Summer 2020 The pros and cons of different delivery modalities for personalised cancer vaccines. Introducing neoantigens directly into a patient in order to elicit an anti-tumour killing immune response is known… Read More

#Exclusive Content

#AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Assay development optimisation & technology #Biomarkers #Business #Cell therapy #Cellular assays #Chemical engineering #Chemistry #Computational chemistry #Drug development #Drug discovery #Enabling technologies #Gene therapy #Genetics / genomics #Genomics #Immunology #Lead discovery #Metabolomics #Molecular medicine #Oncology #Precision medicine #Protein chemistry / Proteomics #RNA #Screening #System biology #Systems biology #Toxicology #Translational #Translational chemistry

Collaborative Research Leads To New Understanding Of Biomarkers

Collaborative Research Leads To New Understanding Of Biomarkers By Dr Max Ryadnov and Professor Jason Crain A new collaborative research paper sheds light on the way antibodies distinguish between different but closely related ‘biomarkers’ – in this case protein fragments which reveal information about the condition of the… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Business #Cell therapy #Cellular & Molecular biology #Cellular assays #Clinical specialities #Drug development #Drug discovery #Drug targets #Gene therapy #High Content Screening #Molecular medicine #Oncology #Protein chemistry / Proteomics #RNA #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Toxicology

Targeting Energy Metabolism for Cancer Therapeutic Discovery using Agilent Seahorse XF Technology

Targeting Energy Metabolism for Cancer Therapeutic Discovery using Agilent Seahorse XF Technology Sponsored by Agilent This white paper discusses targeting energy metabolism for cancer therapeutic discovery using Agilent Seahorse XF technology. Abstract Altered energy metabolism is now recognized as a driver… Read More

#Archive

#Drug discovery #Drug targets #High Content Screening #Immunology #Oncology #Target validation

Gaining Insights Into Disease Biology for Target Identification and Validation

Gaining Insights Into Disease Biology for Target Identification and Validation Sponsored by Agilent Dysfunctional energy metabolism is associated with many different diseases. As such, metabolic modulation is a promising avenue for novel targets in cancer, immunology, and neurological disease. Learn how live-cell metabolic measurements generate critical… Read More

#Archive

#Biologics / Biotechnology #Clinical trials #Gene therapy #Oncology #RNA

Cobra and the KI collaborate to develop COVID-19 vaccine

The Opencorona consortium has awarded €3 million funding by Horizon 2020 to support emergency research and development against the COVID-19 outbreak. Cobra Biologics (Cobra), an international CDMO for biologics and pharmaceuticals, and the Karolinska Institutet (KI), one of the world’s leading medical universities, announced on March 30, they… Read More

#Covid-19 #News

#Drug development #Drug discovery #Drug targets #Immunology #Lead discovery #Oncology #Pathology #PCR #Pharmacology #Protein chemistry / Proteomics #RNA #Stem cells #Therapeutics #Translational #Translational chemistry

Pathios Therapeutics closes US$8.8M Series A and appoints Stuart Hughes as CEO

The financing will accelerate the development of first-in-class therapies in autoimmune disease and immuno-oncology. Pathios Therapeutics Limited (“Pathios”), an innovative biotech company focused on the development of first-in-class therapies for autoimmune diseases and cancer, today announced a US$8.8M Series A financing round with leading international healthcare… Read More

#News

#Cell therapy #Drug development #Drug discovery #Drug targets #Gene therapy #Lead discovery #Oncology #RNA #Stem cells #System biology #Therapeutics

Grey Wolf completes financing to accelerate development of ERAP2 therapies

Grey Wolf Therapeutics completes £2.5 million ($3.3 million) Series A2 financing to accelerate development of therapies targeting ERAP2. Grey Wolf targets ERAP antigen presentation pathways with the aim of ‘illuminating’ non-responsive tumors for attack and destruction by the immune system. Grey Wolf Therapeutics, a drug discovery… Read More

#News

#AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Automation / robotics #Cell therapy #Drug development #Drug discovery #Gene therapy #Immunology #Lead discovery #Oncology #Pathology #Precision medicine #RNA #Screening #Stem cells #Therapeutics

Researchers discover cell communication mechanism that drives cancer adaptation

Collaborative Cancer Research UK-funded studies from University of Oxford researchers have uncovered a new mechanism by which cancer cells adapt to the stresses they encounter as they grow and respond to therapies. This mechanism involves cells releasing small vesicles, known as exosomes. These contain complex mixtures of proteins,… Read More

#Cancer Research #Covid-19 #News

#Business #Drug development #Drug discovery #High Content Screening #Immunology #Immunology / Virology & Vaccines #Lead discovery #Oncology #Preclinical #Regulatory #Stem cells

Cancer Research UK collaborate to develop head and neck cancer vaccine

This a new clinical development partnership to progress a therapeutic DNA vaccine, TGL-100, into an early phase clinical trial targeting head and neck squamous cell carcinoma (HNSCC) HNSCC is the UK’s eighth most common cancer, but treatment options are limited and around 4,000 of those affected in the… Read More

#Cancer Research #News

#Business #Drug development #Drug discovery #Genetics / genomes #Immunology #Oncology #Therapeutics

Horizon Discovery licenses platform to TrueBinding for biotherapeutics development

TrueBinding, a biopharmaceutical company, has signed a set of commercial licenses for Horizon Discovery’s CHOSOURCE platform. TrueBinding will use the cGMP-compliant platform for the development and commercialisation of multiple biotherapeutic products for applications in immuno-oncology and other disease areas with great unmet medical need. Horizon’s CHOSOURCE platform includes a gene-edited… Read More

#News

#Cell therapy #Clinical trials #Gene therapy #Oncology #Preclinical

Collaboration to investigate IMM-101 in difficult to treat cancers

This will explore clinical trials with IMM-101, in combination with other treatments, in difficult to treat cancers, with a particular focus on epithelial cancers such as pancreatic cancer and sarcoma. Immodulon, an immuno-oncology company, and the Champalimaud Foundation, a private, non-profit, research organisation in Lisbon, Portugal, have announced… Read More

#Cancer Research #News

#Oncology

ASCO 2020 Virtual Education Program

Now being held virtually, the upcoming ASCO20 Virtual Education Program, will provide 90 sessions covering topics in cancer education, updates in cancer treatment, professional development, COVID-19, and more. ASCO 2020 Virtual Education Program Now being held virtually, the upcoming ASCO20 Virtual Education Program, will provide 90 sessions covering… Read More

#Covid-19 #News

#Analysis #Drug development #Drug discovery #Genetics / genomics #Genomics #Oncology #RNA

Genetic study says iron levels could be key to ageing slowly

30 July 2020 Image: Sven Mieke Genes linked to ageing that could help explain why some people age at different rates to others have been identified by scientists. The international study using genetic data from more than a million people suggests that maintaining healthy levels of iron in… Read More

#News

#Academic #Assay development optimisation & technology #Business #Cell therapy #Cellular assays #Chemical engineering #Clinical trials #Drug development #Drug discovery #Enabling technologies #Gene editing #Gene therapy #Genomics #High Content Screening #High throughput screening #Imaging #Lead discovery #Microfluidics #Oncology #RNA #Screening #Stem cells #Therapeutics #Toxicology #Translational #Translational chemistry

Merging two immunotherapies may be more effective treatment against some cancers

Some of the most promising advances in cancer treatment have centred on immunotherapies that rev up a patient’s immune system to attack cancer. However, immunotherapies don’t work in all patients, and researchers have been searching for ways to increase their effectiveness. Now, researchers at Washington University School of… Read More

#Cancer Research #News